Temperature Effects on Metabolic Rate of Juvenile Pacific Bluefin Tuna \u3ci\u3eThunnus Orientalis\u3c/i\u3e

Pacific bluefin tuna inhabit a wide range of thermal environments across the Pacific ocean. To examine how metabolism varies across this thermal range, we studied the effect of ambient water temperature on metabolic rate of juvenile Pacific bluefin tuna, Thunnus thynnus, swimming in a swim tunnel. Rate of oxygen consumption (MO2) was measured at ambient temperatures of 8–25°C and swimming speeds of 0.75–1.75 body lengths (BL) s–1. Pacific bluefin swimming at 1 BL s–1 per second exhibited a U-shaped curve of metabolic rate vs ambient temperature, with a thermal minimum zone between 15°C to 20°C. Minimum MO2 of 175±29 mg kg–1 h–1–1 was recorded at 15°C, while both cold and warm temperatures resulted in increased metabolic rates of 331±62 mg kg–1 h–1–1 at 8°C and 256±19 mg kg–1 h–1–1 at 25°C. Tailbeat frequencies were negatively correlated with ambient temperature. Additional experiments indicated that the increase in MO2 at low temperature occurred only at low swimming speeds. Ambient water temperature data from electronic tags implanted in wild fish indicate that Pacific bluefin of similar size to the experimental fish used in the swim tunnel spend most of their time in ambient temperatures in the metabolic thermal minimum zone

Is a specialist breathlessness service more effective and cost-effective for patients with advanced cancer and their carers than standard care? Findings of a mixed-method randomised controlled trial.

BACKGROUND: Breathlessness is common in advanced cancer. The Breathlessness Intervention Service (BIS) is a multi-disciplinary complex intervention theoretically underpinned by a palliative care approach, utilising evidence-based non-pharmacological and pharmacological interventions to support patients with advanced disease. We sought to establish whether BIS was more effective, and cost-effective, for patients with advanced cancer and their carers than standard care. METHODS: A single-centre Phase III fast-track single-blind mixed-method randomised controlled trial (RCT) of BIS versus standard care was conducted. Participants were randomised to one of two groups (randomly permuted blocks). A total of 67 patients referred to BIS were randomised (intervention arm n = 35; control arm n = 32 received BIS after a two-week wait); 54 completed to the key outcome measurement. The primary outcome measure was a 0 to 10 numerical rating scale for patient distress due to breathlessness at two-weeks. Secondary outcomes were evaluated using the Chronic Respiratory Questionnaire, Hospital Anxiety and Depression Scale, Client Services Receipt Inventory, EQ-5D and topic-guided interviews. RESULTS: BIS reduced patient distress due to breathlessness (primary outcome: -1.29; 95% CI -2.57 to -0.005; P = 0.049) significantly more than the control group; 94% of respondents reported a positive impact (51/53). BIS reduced fear and worry, and increased confidence in managing breathlessness. Patients and carers consistently identified specific and repeatable aspects of the BIS model and interventions that helped. How interventions were delivered was important. BIS legitimised breathlessness and increased knowledge whilst making patients and carers feel 'not alone'. BIS had a 66% likelihood of better outcomes in terms of reduced distress due to breathlessness at lower health/social care costs than standard care (81% with informal care costs included). CONCLUSIONS: BIS appears to be more effective and cost-effective in advanced cancer than standard care. TRIAL REGISTRATION: RCT registration at ClinicalTrials.gov NCT00678405 (May 2008) and Current Controlled Trials ISRCTN04119516 (December 2008).The study was supported by the following funders: NIHR Research for Patient Benefit (for Phase III RCT funding); Macmillan Cancer Support (MF’s post-doctoral fellowship); The Gatsby Foundation for the initial funding of BIS; and AT Prevost was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. The study sponsor was CUHNFT.This is the final published version. It first appeared at http://www.biomedcentral.com/1741-7015/12/194

G313.3+00.3: A New Planetary Nebula discovered by the Australia Telescope Compact Array and the Spitzer Space Telescope

We present a new planetary nebula, first identified in images from the Australia Telescope Compact Array, although not recognized at that time. Recent observations with the Spitzer Space Telescope during the GLIMPSE Legacy program have rediscovered the object. The high-resolution radio and infrared images enable the identification of the central star or its wind, the recognition of the radio emission as thermal, and the probable presence of polycylic aromatic hydrocarbons in and around the source. These lead to the conclusion that G313.3+00.3 is a planetary nebula. This object is of particular interest because it was discovered solely through radio and mid-infrared imaging, without any optical (or near-infrared) confirmation, and acts as a proof of concept for the discovery of many more highly extinguished planetary nebulae. G313.3+00.3 is well-resolved by both the instruments with which it was identified, and suffers extreme reddening due to its location in the Scutum-Crux spiral arm.Comment: 18 pages, LaTeX (aastex), incl. 8 PostScript (eps) figures and 1 table. Accepted by ApJ (Part 1

Sex-Stratified Genome-Wide Association Study of Multisite Chronic Pain in UK Biobank

Chronic pain is highly prevalent worldwide and imparts a significant socioeconomic and public health burden. Factors influencing susceptibility to, and mechanisms of, chronic pain development, are not fully understood, but sex is thought to play a significant role, and chronic pain is more prevalent in women than in men. To investigate sex differences in chronic pain, we carried out a sex-stratified genome-wide association study of Multisite Chronic Pain (MCP), a derived chronic pain phenotype, in UK Biobank on 178,556 men and 209,093 women, as well as investigating sex-specific genetic correlations with a range of psychiatric, autoimmune and anthropometric phenotypes and the relationship between sex-specific polygenic risk scores for MCP and chronic widespread pain. We also assessed whether MCP-associated genes showed expression pattern enrichment across tissues. A total of 123 SNPs at five independent loci were significantly associated with MCP in men. In women, a total of 286 genome-wide significant SNPs at ten independent loci were discovered. Meta-analysis of sex-stratified GWAS outputs revealed a further 87 independent associated SNPs. Gene-level analyses revealed sex-specific MCP associations, with 31 genes significantly associated in females, 37 genes associated in males, and a single gene, DCC, associated in both sexes. We found evidence for sex-specific pleiotropy and risk for MCP was found to be associated with chronic widespread pain in a sex-differential manner. Male and female MCP were highly genetically correlated, but at an rg of significantly less than 1 (0.92). All 37 male MCP-associated genes and all but one of 31 female MCP-associated genes were found to be expressed in the dorsal root ganglion, and there was a degree of enrichment for expression in sex-specific tissues. Overall, the findings indicate that sex differences in chronic pain exist at the SNP, gene and transcript abundance level, and highlight possible sex-specific pleiotropy for MCP. Results support the proposition of a strong central nervous-system component to chronic pain in both sexes, additionally highlighting a potential role for the DRG and nociception

Epidemiologia kliniczna depresji w opiece paliatywnej i wartość predykcyjna objawów somatycznych — przekrojowe badanie ankietowe z 4-tygodniowym okresem obserwacji

Celem przedstawionego w niniejszej pracy przekrojowego badania ankietowego było określenie rozpowszechnienia i remisji depresji u pacjentów objętych opieką paliatywną oraz oszacowanie wartości predykcyjnej objawów somatycznych w ustalaniu rozpoznania wspomnianego schorzenia. Z 300 kolejnymi pacjentami przeprowadzono wywiady w ciągu tygodnia od pierwszej oceny diagnostycznej przez pielęgniarkę specjalistyczną z placówki zajmującej się stacjonarną i domową opieką paliatywną w południowym Londynie (Wielka Brytania). Oceny pod kątem występowania depresji dokonywano, korzystając z kwestionariusza PRIME-MD PHQ-9. Obecność objawów somatycznych ustalono na podstawie kwestionariusza oceny jakości życia EORTC-QLQ-C30. Kryteria rozpoznawcze dużego zaburzenia depresyjnego zostały spełnione w przypadku 58 pacjentów [19,3% (15,3&#8211;23,3%)], a kryteria dowolnego zespołu depresyjnego &#8212; w przypadku 109 pacjentów [36,3% (32,3&#8211;40,3%)]. Wśród chorych z dużym zaburzeniem depresyjnym więcej było osób płci męskiej, częściej notowano brak nowotworu złośliwego, dolegliwości bólowe, zły stan ogólny i pragnienie szybkiej śmierci. Spośród chorych z dużym zaburzeniem depresyjnym stwierdzonym na początku badania u 69% (27/39) pacjentów odnotowano remisję depresji 4 tygodnie później. Wśród chorych bez depresji na początku badania u 11% (19/174) osób stwierdzono spełnienie kryteriów tego schorzenia podczas wizyty kontrolnej. Wartości predykcyjne dodatnie zaburzeń snu, obniżonego łaknienia i zmęczenia były niskie (< 24%), natomiast wartości predykcyjne ujemne tych objawów &#8212; wysokie (> 89%). Duże rozpowszechnienie depresji wśród pacjentów objętych opieką paliatywną świadczy o konieczności dokonywania oceny psychologicznej tych osób i udzielania im wsparcia psychologicznego. Przebieg depresji u pacjentów objętych opieką paliatywną charakteryzuje się małą stabilnością, w związku z czym jej objawy powinno się uważnie monitorować

Identification of human viral protein-derived ligands recognized by individual MHCI-restricted T-cell receptors

Evidence indicates that autoimmunity can be triggered by virus-specific CD8+ T cells that crossreact with self-derived peptide epitopes presented on the cell surface by major histocompatibility complex class I (MHCI) molecules. Identification of the associated viral pathogens is challenging because individual T-cell receptors can potentially recognize up to a million different peptides. Here, we generate peptide length-matched combinatorial peptide library (CPL) scan data for a panel of virus-specific CD8+ T-cell clones spanning different restriction elements and a range of epitope lengths. CPL scan data drove a protein database search limited to viruses that infect humans. Peptide sequences were ranked in order of likelihood of recognition. For all anti-viral CD8+ T-cell clones examined in this study, the index peptide was either the top-ranked sequence or ranked as one of the most likely sequences to be recognized. Thus, we demonstrate that anti-viral CD8+ T-cell clones are highly focused on their index peptide sequence and that ‘CPL-driven database searching’ can be used to identify the inciting virus-derived epitope for a given CD8+ T-cell clone. Moreover, to augment access to CPL-driven database searching, we have created a publicly accessible webtool. Application of these methodologies in the clinical setting may clarify the role of viral pathogens in the etiology of autoimmune diseases